Effective lifecycle management across multiple approved ANDAs requires structured oversight of Annual Reports and post-approval changes. When reporting gaps and misclassified changes created compliance risk, we, at Vigilare, conducted a rapid gap assessment and implemented a comprehensive corrective strategy.
Our team reviewed historical submissions, re-evaluated post-approval changes adhering to the FDA guidance, and supported the preparation of appropriate supplemental filings to restore regulatory alignment. In parallel, we established a structured Annual Report planning and tracking framework to prevent future gaps.
The engagement resulted in the successful execution of approximately 250 submissions to the US FDA, improved lifecycle governance, and strengthened long-term compliance confidence across the ANDA portfolio. Learn more about the successful submissions in this case study. Download.
Comments are closed